Butterfly Network (BFLY) Earnings Date & Reports

Key Takeaways

• Record quarterly revenue: Butterfly Network posted $32.6 million in total revenue for Q2 2026, a 39% increase year-over-year and above the high end of the company's guidance.
• Adjusted EPS beat estimates: The company reported an adjusted loss of $0.01 per share, handily beating the consensus estimate of a $0.03 loss.
• Gross margin hit an all-time high: Gross margin reached 71.4%, up 770 basis points from 63.7% a year earlier, driven by high-margin Embedded licensing revenue.
• Embedded revenue surged 439%: Revenue from the Butterfly Embedded™ partnership program jumped to $10.8 million, reflecting milestone progress on co-development agreements.
• Full-year guidance raised: Butterfly lifted its FY 2026 revenue outlook to $119–$123 million and improved its adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) loss guidance.
• International sales softened: International revenue declined 14% to $5.0 million, pressured by delayed deals and difficult prior-year comparisons.

Earnings Context and Why It Matters

Butterfly Network's Q2 2026 results land at a pivotal moment for the semiconductor-based ultrasound company. Coming off a strong Q1 where revenue of $26.5 million topped estimates, investors were watching closely to see whether the company's multi-engine growth strategy—spanning its core POCUS (point-of-care ultrasound) business, the fast-growing Embedded licensing program, and an emerging Home & Community Care segment—could sustain momentum. With shares up roughly 87% year-to-date heading into the report, market expectations were elevated. This quarter's results offer the clearest evidence yet that Butterfly's Embedded partnerships are transitioning from a promising narrative to a material revenue driver, while also revealing the complexities of managing international distribution and product mix.

Reported Results

Butterfly Network reported total revenue of $32.6 million for the second quarter ended June 30, 2026, surpassing both the Zacks Consensus Estimate of approximately $28.4 million and the company's own guidance range. U.S. revenue climbed 57% to $27.6 million, fueled by Embedded partnership milestones—most notably co-development work with Midjourney—as well as higher probe sales to health systems, medical schools, and e-commerce customers.

Adjusted EPS came in at a loss of $0.01, a significant improvement over the $0.03 loss analysts had expected and the $0.03 adjusted loss posted in the same quarter last year. On a GAAP (Generally Accepted Accounting Principles) basis, EPS was a loss of $0.05, compared to a loss of $0.06 in Q2 2025. Net loss narrowed to $12.9 million from $13.8 million a year earlier.

Gross margin was a standout metric: at 71.4%, it marked the highest in company history and reflected the favorable mix shift toward high-margin Embedded licensing revenue. Adjusted EBITDA loss improved 78% year-over-year to just $1.4 million, also beating guidance. Operating expenses rose 19% to $37.0 million, driven by increased headcount to support revenue growth and product development. Cash and cash equivalents stood at $124.7 million as of June 30, 2026.

Notably, the company raised its full-year 2026 revenue guidance to $119–$123 million (22%–26% growth) and improved its adjusted EBITDA loss forecast to $19–$23 million. For Q3 2026, Butterfly guided for revenue of $26–$30 million and an adjusted EBITDA loss of $6–$9 million.

AI Screener

For investors seeking to identify stocks with similar momentum or to track emerging opportunities across the healthcare technology sector, Tickeron's AI Screener offers a powerful AI-driven discovery tool. The platform enables users to filter thousands of stocks and ETFs using customizable criteria including technical indicators, fundamental metrics, volatility patterns, and proprietary AI-generated signals. Whether scanning for breakout candidates, trend-following setups, or stocks exhibiting specific price patterns, the AI Screener helps streamline the research process and uncover trade ideas that manual screening might miss. Explore the screener to see how AI-powered filtering can enhance your market analysis workflow.

Market Reaction and Investor Sentiment

Heading into the Q2 release, sentiment around Butterfly Network was broadly positive, though not without caution. The stock's year-to-date rally had already priced in considerable optimism, and the risk of a "sell-the-news" reaction was present given elevated valuation multiples—the company's price-to-sales ratio sat near 17, well above its historical median. Early indications following the July 30 release showed the market responding favorably to the revenue beat and guidance raise, with particular enthusiasm around the 439% surge in Embedded revenue and the path toward near-breakeven adjusted EBITDA. Still, the 14% international revenue decline and the modest 2% growth in core POCUS revenue served as reminders that not all segments are firing equally. Investors appeared to weigh the transformative potential of the Embedded model against the uneven performance of the legacy distribution business.

Forward Outlook and Key Factors to Monitor

Looking ahead, Butterfly Network's trajectory will be shaped by several key developments unfolding over the remainder of fiscal 2026.

The Embedded partnership program now stands at 11 partners and is clearly the company's most consequential growth engine. With two new partners added during Q2 and high-profile collaborators like Midjourney and Aleph Neuro publicly showcasing applications built on Butterfly's Ultrasound-on-Chip™ platform, the pipeline appears robust. Management guided for embedded revenue in the $7–$8 million per-quarter range, with potential upside as additional partners progress through development milestones. The real inflection point will come when these partners begin commercializing their products—an event the company anticipates for some current partners in the future, though exact timelines remain uncertain.

On the regulatory and market-access front, Butterfly received authorization in Brazil during the quarter, opening a door to one of the world's largest ultrasound markets. This, combined with progress toward FedRAMP (Federal Risk and Authorization Management Program) certification expected in Q3 2026 and provisional authorization to sell across the U.S. Department of Veterans Affairs, could unlock meaningful government and enterprise opportunities.

Several headwinds merit attention. International revenue remains a weak point, down 14% year-over-year, and the company acknowledged macroeconomic risks from tariffs, AI-driven supply chain constraints, and geopolitical tensions. The Home & Community Care segment is still pre-revenue, with the first commercial implementation expected only in Q4 2026, meaning near-term contributions will be minimal. Additionally, operating expenses continue to rise as Butterfly invests in headcount and infrastructure, testing the company's ability to balance growth with the march toward profitability. Cash from operations turned more negative at $13.3 million used, compared to $7 million in the prior-year quarter.

Investors should monitor Embedded partner commercialization announcements, the pace of new partnership signings, and whether international revenue can stabilize in the second half of the year. The raised guidance provides a clearer roadmap, but execution across all three growth engines will be critical to sustaining market confidence.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations